NOVO.B.DK

451.65

+3.16%↑

COLO.B.DK

602.8

+1.17%↑

GMAB.DK

1,298

+0.46%↑

ZEAL.DK

374

+3.17%↑

AMBUB.DK

99.65

+0.86%↑

NOVO.B.DK

451.65

+3.16%↑

COLO.B.DK

602.8

+1.17%↑

GMAB.DK

1,298

+0.46%↑

ZEAL.DK

374

+3.17%↑

AMBUB.DK

99.65

+0.86%↑

NOVO.B.DK

451.65

+3.16%↑

COLO.B.DK

602.8

+1.17%↑

GMAB.DK

1,298

+0.46%↑

ZEAL.DK

374

+3.17%↑

AMBUB.DK

99.65

+0.86%↑

NOVO.B.DK

451.65

+3.16%↑

COLO.B.DK

602.8

+1.17%↑

GMAB.DK

1,298

+0.46%↑

ZEAL.DK

374

+3.17%↑

AMBUB.DK

99.65

+0.86%↑

NOVO.B.DK

451.65

+3.16%↑

COLO.B.DK

602.8

+1.17%↑

GMAB.DK

1,298

+0.46%↑

ZEAL.DK

374

+3.17%↑

AMBUB.DK

99.65

+0.86%↑

Search

H Lundbeck A-S

Closed

35.54 1.43

Overview

Share price change

24h

Current

Min

35.34

Max

35.56

Key metrics

By Trading Economics

Income

562M

1.2B

Sales

694M

6.2B

P/E

Sector Avg

11

40.527

EPS

1.53

Dividend yield

2.61

Profit margin

18.476

Employees

5,700

EBITDA

811M

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.61%

2.40%

Market Stats

By TradingEconomics

Market Cap

-1.8B

35B

Previous open

34.11

Previous close

35.54

H Lundbeck A-S Chart

Past performance is not a reliable indicator of future results.

Related News

4 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 Jul 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Received All Required Authorizations

4 Jul 2025, 15:48 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 Jul 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 Jul 2025, 14:30 UTC

Acquisitions, Mergers, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 Jul 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 Jul 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 Jul 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 Jul 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 Jul 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 Jul 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Jul 2025, 12:02 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

Peer Comparison

Price change

H Lundbeck A-S Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.